A part of Watch Media

MedWatchTuesday3 October 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchTuesday3 October 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Regulation

EU deal forces large firms to share tax information

From 2023 onwards, multinational companies with an annual revenue above EUR 750m will have to publicize how much tax they pay in the 27 member countries of the EU, and how much they pay in countries on the EU's tax haven blacklist.
Photo: Thomas Borberg/Ritzau Scanpix
Photo: Thomas Borberg/Ritzau Scanpix
BY RITZAU FINANS AND ALBERT RØNNING ANDERSSON, TRANSLATED BY NIELSINE NIELSEN

On Tuesday, the European Parliament and the governments of the EU countries agreed on a deal which will force multinational companies to publish their tax information, according to news agency Reuters.

More specifically, large global companies with annual revenues surpassing EUR 750m (USD 915.4m) will have to give information on how much tax they are paying in the 27 member countries of the EU, and how much they pay in countries on the EU's tax haven blacklist.

The companies will be obliged to share information on their income and number of employees in the EU and in other countries on their websites.

Attempts at closing this deal had been at a standstill since 2016.

The deal is part of the EU's efforts to combat the tax evasion by large multinational companies. The EU is in dire need of finances to get the economy back and running after the covid-19 pandemic.

The European Parliament calls the deal a milestone in an announcement, but multiple organizations criticize the deal for not being sufficiently comprehensive.

Non-governmental organizations such as Transparency International, Oxfam, Eurodad and Public Services International are a few of the companies which have criticized the reach of the deal, according to Politico.

The NGOs are particularly unsatisfied with the fact that multinational companies will only be forced to share detailed tax information from the EU and countries on the EU's blacklist of tax havens, but not from the rest of the world.

"This means that companies’ operations in most of the world will still be exempt from public scrutiny," says Transparency International Senior Policy Officer Elena Gaita.

She adds that "the proposed legislation as it stands is almost meaningless."

Novo Nordisk divulges tax payments in other countries

Currently, the EU's list of tax havens includes 21 countries. According to Oxfam, this means more than three quarters of the world's almost 200 countries are exempt from the new regulation.

Politico reports that during negotiations, the EU parliament tried to include global activities in the new deal. The majority of the EU governments turned this down.

In spite of the criticism, the media states that the European Commissioner for Economy, Paolo Gentiloni, calls the deal a step in the right direction.

According to the Tax Justice Network, 36 percent of all lost tax income globally comes from EU member countries. The firms' tax evasion costs the world's countries around USD 154bn globally.

In Denmark, Novo Nordisk announced in February that it would present its tax payments at a regional level, and it will report intellectual rights conditions, the extent of production and the regional distribution of its total sales.

Coloplast is also taking tax payment transparency into consideration. The medtech company has previously been put under pressure by multiple large pension funds, who have called for more transparency from the firm.

In 2019, Novo Nordisk owner Novo Holdings was once again the largest tax payer in Denmark with tax payments amounting to just over DKK 8.2bn, equivalent to a 16.1 percent increase compared with 2018 where Novo Holdings paid DKK 7.06bn.

New regulation means stricter requirements for medtech firms 

Global tax agreement could prompt Novo Nordisk to take tax payments elsewhere 

Novo Nordisk increases transparency on tax payments 

Share article

Related articles:

  • New regulation means stricter requirements for medtech firms

    For subscribers

  • Photo: Tidsvilde Stine/Ritzau Scanpix

    Global tax agreement could prompt Novo Nordisk to take tax payments elsewhere

    For subscribers

  • Photo: Stine Tidsvilde

    Novo Nordisk increases transparency on tax payments

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Foto: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.
  • FDA to review Novo Nordisk drug for rare metabolic disease
  • Huge acquisition scores Novo Nordisk an FDA-ready treatment

For subscribers



Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr
Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers



Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers


Foto: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug


Foto: Yuriko Nakao/Reuters/Ritzau Scanpix
Medtech

Olympus appoints new chief medical officer

For subscribers


Foto: Alexander Heinl/AP/Ritzau Scanpix
Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

For subscribers


  • Vaccine breakthrough behind mRNA shots wins Nobel Prize

    The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.

    For subscribers


  • Foto: Ws Audiology / Pr

    WS Audiology hires new chief technology officer from car manufacturer

    He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.

    For subscribers


  • Foto: Tom Little

    Novo Nordisk files lawsuit against US authorities ahead of price negotiation

    The litigation is the latest in a long line of industry lawsuits related to price negotiations.

    For subscribers


  • Foto: Mike Segar

    FDA rejects atopic dermatitis drug lebrikizumab

    Eli Lilly had expected a launch this year.

    For subscribers


  • The FDA has updated the package label of Novo Nordisk's diabetes drug, Ozempic, with a warning about intestinal blockage disorder as a possible side effect. | Foto: Tom Little/Reuters/Ritzau Scanpix

    FDA updates Novo Nordisk's Ozempic drug label with side effect alert

    The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.

    For subscribers


  • Foto: Anushree Fadnavis/Reuters/Ritzau Scanpix

    Country Manager: Indians will have to wait for Wegovy until 2026

    Up to 40% of the female population aged 30-49 in India is overweight.

    For subscribers


Further reading

Foto: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers



Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr
Pharma & biotech

Fujifilm expands management with former Leo executive

The contract manufacturer has hired a chief people officer with immediate effect.

For subscribers



Foto: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

Foto: Alexander Heinl/AP/Ritzau Scanpix
Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.

For subscribers



Genmab CEO Jan van de Winkel and director general of The Confederation of Danish Industry, Lars Sandahl Sørensen. | Foto: Genmab / PR
Pharma & biotech

Genmab has officially opened its new headquarters

The CEO describes the new premises as a symbol of the company’s commitment to advancing science and innovation.

For subscribers



Foto: Ws Audiology / Pr
Hearing health

WS Audiology hires new chief technology officer from car manufacturer

He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.

For subscribers


Jobs

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Senior QA Specialists (GMP or GCP)

  • Director, Head of Antibody Technology

  • Audit & Supplier Manager

  • Clinical Supply Manager

  • Scientist - Bioanalysis, Biologics

  • Clinical Trial Manager

  • Project Director, HR & ESG

  • Global Medical Manager

  • VP of Software Development, Perfusion Tech

  • Senior Analytical Scientists

  • Supply Value Stream (SVS) Project Manager

  • Qualified Person to AJ Vaccines

  • QA/RA Manager

  • Senior Legal Councel

See all jobs

Latest news

  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
  • Olympus appoints new chief medical officer –
  • Low share price may knock Galecto off the stock exchange –
  • Fujifilm expands management with former Leo executive –
  • Snack maker keeps an eye on Novo Nordisk's obesity drug –
  • FDA approves Novo Nordisk drug to treat rare condition –
  • FDA updates Novo Nordisk's Ozempic drug label with side effect alert –
  • FDA rejects atopic dermatitis drug lebrikizumab –
  • FDA to support new orphan drugs through pilot program –
  • Vaccine breakthrough behind mRNA shots wins Nobel Prize –
See all

Jobs

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Senior QA Specialists (GMP or GCP)

  • Director, Head of Antibody Technology

  • Audit & Supplier Manager

  • Clinical Supply Manager

  • Scientist - Bioanalysis, Biologics

  • Clinical Trial Manager

  • Project Director, HR & ESG

  • Global Medical Manager

  • VP of Software Development, Perfusion Tech

  • Senior Analytical Scientists

  • Supply Value Stream (SVS) Project Manager

  • Qualified Person to AJ Vaccines

  • QA/RA Manager

  • Senior Legal Councel

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved